Recent Updates
  • The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10%

    Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies.

    Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market (2nd Edition), 2022-2035” report to its list of offerings.

    The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers.

    Key Market Insights

    Over 150 companies claim to offer companion diagnostics development services, globally
    Nearly 60% of the aforementioned players are based in North America, followed by the players located in Europe (30%). Further, this segment of the industry is dominated by the presence of mid-sized players (51-200 employees), which represent 40% of the total service providers.

    Nearly 15% players claim to act as one-stop shops, offering services, ranging from biomarker discovery and development to manufacturing and commercialization
    Most of the service providers (127) provide assay development services, followed by companies (124) offering services for biomarker discovery / identification. Further, NGS is the most popular technique, employed by over 100 service providers.

    Over 90 companies are actively involved in the development of companion diagnostics
    Nearly 91% of the total tests can detect mutations in a single biomarker. Amongst these, ErbB gene family (HER-2 and EGFR genes), PD-L1 genes, RAS gene family (KRAS and NRAS genes), BRCA gene family (BRCA1 and BRCA2) and BRAF emerged as the key genes which are assessed by majority of the companion diagnostics.

    Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2021
    Mergers and acquisitions, product development agreements and product development and commercialization agreements account for more than 60% of the total number of deals inked during the given time period. It is worth highlighting that nearly 25% of the total number of deals were signed in 2021. Further, the maximum number (177) of partnerships have been inked for companion diagnostics being developed for the treatment of oncological disorders.


    North America is expected to capture ~60% share in the companion diagnostics development services market by 2035
    Owing to the high costs associated with the clinical validation of companion diagnostics, a significant proportion (~46%) of service revenues is generated from this step, in 2035. In terms of analytical technique used, service contracts involving NGS are anticipated to contribute to more than 35% of the total service revenues generated in 2035. Further, close to 90% of the total service revenues, in 2035, are generated from companion diagnostics development projects for cancer indications.


    To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/297/request-sample.html

    One of the key objectives of the report was to estimate the existing companion diagnostics market size and the potential future growth opportunities for companion diagnostics development service providers. Based on multiple parameters, such as the service cost of various steps involved in companion diagnostics development and manufacturing, and partnerships inked in the last few years for outsourcing of such operations, we have developed informed estimates on the evolution of the market for the time period 2022- 2035. An insightful analysis of companies segregated on the basis of their likelihood to enter into collaborations with companion diagnostics service providers. The chapter features a list of 300+ drug developers sponsoring clinical trials of therapies targeting several disease-specific biomarkers. The players have been shortlisted based on relevant parameters, namely number of biomarker-focused clinical trials sponsored and the time to market their proprietary personalized medicine products.


    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html or email sales@rootsanalysis.com


    You may also be interested in the following titles:
    1. Targeted protein degradation market, 2022-2035
    2. Cell Therapy Manufacturing Market, 2021-2030
    3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10% Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies. Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market (2nd Edition), 2022-2035” report to its list of offerings. The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers. Key Market Insights Over 150 companies claim to offer companion diagnostics development services, globally Nearly 60% of the aforementioned players are based in North America, followed by the players located in Europe (30%). Further, this segment of the industry is dominated by the presence of mid-sized players (51-200 employees), which represent 40% of the total service providers. Nearly 15% players claim to act as one-stop shops, offering services, ranging from biomarker discovery and development to manufacturing and commercialization Most of the service providers (127) provide assay development services, followed by companies (124) offering services for biomarker discovery / identification. Further, NGS is the most popular technique, employed by over 100 service providers. Over 90 companies are actively involved in the development of companion diagnostics Nearly 91% of the total tests can detect mutations in a single biomarker. Amongst these, ErbB gene family (HER-2 and EGFR genes), PD-L1 genes, RAS gene family (KRAS and NRAS genes), BRCA gene family (BRCA1 and BRCA2) and BRAF emerged as the key genes which are assessed by majority of the companion diagnostics. Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2021 Mergers and acquisitions, product development agreements and product development and commercialization agreements account for more than 60% of the total number of deals inked during the given time period. It is worth highlighting that nearly 25% of the total number of deals were signed in 2021. Further, the maximum number (177) of partnerships have been inked for companion diagnostics being developed for the treatment of oncological disorders. North America is expected to capture ~60% share in the companion diagnostics development services market by 2035 Owing to the high costs associated with the clinical validation of companion diagnostics, a significant proportion (~46%) of service revenues is generated from this step, in 2035. In terms of analytical technique used, service contracts involving NGS are anticipated to contribute to more than 35% of the total service revenues generated in 2035. Further, close to 90% of the total service revenues, in 2035, are generated from companion diagnostics development projects for cancer indications. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/297/request-sample.html One of the key objectives of the report was to estimate the existing companion diagnostics market size and the potential future growth opportunities for companion diagnostics development service providers. Based on multiple parameters, such as the service cost of various steps involved in companion diagnostics development and manufacturing, and partnerships inked in the last few years for outsourcing of such operations, we have developed informed estimates on the evolution of the market for the time period 2022- 2035. An insightful analysis of companies segregated on the basis of their likelihood to enter into collaborations with companion diagnostics service providers. The chapter features a list of 300+ drug developers sponsoring clinical trials of therapies targeting several disease-specific biomarkers. The players have been shortlisted based on relevant parameters, namely number of biomarker-focused clinical trials sponsored and the time to market their proprietary personalized medicine products. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Companion Diagnostics Development Services Market | Industry Analysis | Market Size | 2035
    Market research report focused on companion diagnostics service providers; details include current market landscape and future growth opportunities
    0 Comments 0 Shares
  • The cell invasion and migration assays market is projected to grow at a CAGR of 8% during the period 2022-2035, claims Roots Analysis

    In recent years, the potential of cell invasion and migration assays with respect to discovery, diagnosis and screening of diseases has been widely recognized, which has further presented lucrative opportunities for players offering such products.

    London
    Roots Analysis has announced the addition of the “Cell Invasion and Migration Assays Market, 2022–2035” report to its list of offerings.
    Owing to several advantages offered by cell invasion and migration assays in analyzing and quantifying cellular mechanisms, industry stakeholders have undertaken numerous R&D initiatives focused on exploiting the use of such assays to expediate discovery timelines and optimize the total development cost. Considering the various advantages offered by these cell-based assays, researchers across the globe have undertaken several initiatives to use these platforms for the diagnosis of a myriad of disease indications. The advancements in various technologies have propelled life science companies to use these assays in the drug discovery process, to enable the identification of potential lead candidates.

    To request a sample copy / brochure of this report, please visit this
    https://www.rootsanalysis.com/reports/cell-invasion-and-migration-assays-market/request-sample.html

    Key Market Insights
    Presently, more than 80% of the total assay providers are based in North America
    This segment of the industry is dominated by the presence of companies that were established pre-2000 (64%), followed by firms established during 2000-2010 (27%). In addition, most of the players engaged in this domain are small firms (less than 100 employees), representing over 45% of the total assay providers.

    Currently, over 80 cell invasion and migration assays are available in the market
    It is worth noting that most of the cell invasion and migration assays are currently being used for tumor studies (89%), followed by those employed for screening purposes (79%). Further, most of the assays are being developed for adherent cell cultures (48%), followed by those being manufactured for both adherent and suspension cell cultures (40%).

    55% players claim to be capable of offering both cell invasion as well as cell migration assays
    64% of the cell invasion and migration assays can be stored under frozen temperature (-18°C to -40°C), followed by those stored under refrigerated conditions (+1°C to +18°C) (36%). Further, it is worth noting that most of the cell invasion and migration assays are being used to conduct 100 tests (37%). This was followed by assays being developed to conduct 12 (35%) and 96 tests (23%).

    Over 650 articles focused on cell invasion and migration assays have been published, since 2021
    Majority of the scientific literature published in this domain was focused on research (96%), followed by review articles (4%). It is worth mentioning that articles related to cell invasion and migration assays have been affiliated by over 300 universities.

    For additional details, please visit
    https://www.rootsanalysis.com/reports/cell-invasion-and-migration-assays-market.html

    You may also be interested in the following titles:
    1. Targeted protein degradation market, 2022-2035
    2. Cell Therapy Manufacturing Market, 2021-2030
    3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/

    The cell invasion and migration assays market is projected to grow at a CAGR of 8% during the period 2022-2035, claims Roots Analysis In recent years, the potential of cell invasion and migration assays with respect to discovery, diagnosis and screening of diseases has been widely recognized, which has further presented lucrative opportunities for players offering such products. London Roots Analysis has announced the addition of the “Cell Invasion and Migration Assays Market, 2022–2035” report to its list of offerings. Owing to several advantages offered by cell invasion and migration assays in analyzing and quantifying cellular mechanisms, industry stakeholders have undertaken numerous R&D initiatives focused on exploiting the use of such assays to expediate discovery timelines and optimize the total development cost. Considering the various advantages offered by these cell-based assays, researchers across the globe have undertaken several initiatives to use these platforms for the diagnosis of a myriad of disease indications. The advancements in various technologies have propelled life science companies to use these assays in the drug discovery process, to enable the identification of potential lead candidates. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/cell-invasion-and-migration-assays-market/request-sample.html Key Market Insights Presently, more than 80% of the total assay providers are based in North America This segment of the industry is dominated by the presence of companies that were established pre-2000 (64%), followed by firms established during 2000-2010 (27%). In addition, most of the players engaged in this domain are small firms (less than 100 employees), representing over 45% of the total assay providers. Currently, over 80 cell invasion and migration assays are available in the market It is worth noting that most of the cell invasion and migration assays are currently being used for tumor studies (89%), followed by those employed for screening purposes (79%). Further, most of the assays are being developed for adherent cell cultures (48%), followed by those being manufactured for both adherent and suspension cell cultures (40%). 55% players claim to be capable of offering both cell invasion as well as cell migration assays 64% of the cell invasion and migration assays can be stored under frozen temperature (-18°C to -40°C), followed by those stored under refrigerated conditions (+1°C to +18°C) (36%). Further, it is worth noting that most of the cell invasion and migration assays are being used to conduct 100 tests (37%). This was followed by assays being developed to conduct 12 (35%) and 96 tests (23%). Over 650 articles focused on cell invasion and migration assays have been published, since 2021 Majority of the scientific literature published in this domain was focused on research (96%), followed by review articles (4%). It is worth mentioning that articles related to cell invasion and migration assays have been affiliated by over 300 universities. For additional details, please visit https://www.rootsanalysis.com/reports/cell-invasion-and-migration-assays-market.html You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Cell Invasion and Migration Assays Market | Industry Analysis | Market Size | 2035
    Cell Invasion and Migration Assay Market report features an extensive study of the current market landscape and the likely future potential...
    0 Comments 0 Shares
  • The novel antibody therapies market for advanced stage drugs is anticipated to grow at a CAGR of 36% by 2035, claims Roots Analysis

    Owing to the recent approval of therapies, such as Elzonris®, Pluvicto®, there has been a substantial increase in the R&D activity to evaluate the use of novel antibody therapy candidates for the treatment of a variety of disease indications.

    Roots Analysis has announced the addition of “Novel Antibody Therapies Market, 2022-2035” report to its list of offerings.

    Antibodies are the key components of immune system that bind to specific markers on cells or tissues, thereby offering first line of defense against multiple disorders. This has opened a new target space for the development of antibody therapeutics and techniques, facilitating tools to uniquely distinct malignantly transformed cells from regular cells.

    To request a sample copy / brochure of this report, please visit
    https://www.rootsanalysis.com/reports/novel-antibody-therapies-market/request-sample.html

    Key Market Insights

    Presently, 140+ novel antibody therapies have been marketed / are being evaluated across different phases of development for the treatment of various disease indications
    Till date, five novel antibody therapies have been marketed and close to 80% of the pipeline candidates are under clinical evaluation. It is worth mentioning that most of the drug candidates are immunotoxins (34%), followed by immunocytokines (32.5%). Majority of these therapies are under clinical trials for the treatment of lymphoma (22) followed by solid tumors (19) and leukemia (18).

    Around 60 industry and non-industry players are engaged in the development of novel antibody therapies, globally
    North America has emerged as the hub, featuring the presence of approximately 60% developers. The market is currently dominated by the presence of small players (27%). Interestingly, 16% of the players are big pharma companies engaged in the development of such therapeutics for multiple target indications.

    More than 550 clinical trials have been registered for the evaluation of novel antibody therapies, worldwide
    The clinical research activity, in terms of number of trials registered, is reported to have increased at a steady CAGR of 8%, during the period 2016-2021. Of the total number of trials registered, close to 60% have already been completed, while 25% of the studies are actively recruiting participants.

    Close to 600 articles related to novel antibody therapies, have been published in reputed scientific journals, since 2017
    More than 95% of the articles focused on novel antibody therapies were published post-2019. Popular journals that have published multiple articles include Cancer, Frontiers in Immunology, International Journal of Molecular Sciences and Scientific Reports.

    Over 4,600 patents have been filed / granted related to novel antibody therapies, since 2017
    More than 1,150 patents were filed / granted in 2021. Further, around 56% of the patents were filed in North America. It is worth highlighting that majority of the patents were granted / filed by prominent industry / non-Industry players, such as Novartis, Hoffmann la Roche, Immatics Biotechnologies
    and Pfizer.

    For additional details, please visit https://www.rootsanalysis.com/reports/novel-antibody-therapies-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Targeted protein degradation market, 2022-2035
    2. Cell Therapy Manufacturing Market, 2021-2030
    3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/

    The novel antibody therapies market for advanced stage drugs is anticipated to grow at a CAGR of 36% by 2035, claims Roots Analysis Owing to the recent approval of therapies, such as Elzonris®, Pluvicto®, there has been a substantial increase in the R&D activity to evaluate the use of novel antibody therapy candidates for the treatment of a variety of disease indications. Roots Analysis has announced the addition of “Novel Antibody Therapies Market, 2022-2035” report to its list of offerings. Antibodies are the key components of immune system that bind to specific markers on cells or tissues, thereby offering first line of defense against multiple disorders. This has opened a new target space for the development of antibody therapeutics and techniques, facilitating tools to uniquely distinct malignantly transformed cells from regular cells. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/novel-antibody-therapies-market/request-sample.html Key Market Insights Presently, 140+ novel antibody therapies have been marketed / are being evaluated across different phases of development for the treatment of various disease indications Till date, five novel antibody therapies have been marketed and close to 80% of the pipeline candidates are under clinical evaluation. It is worth mentioning that most of the drug candidates are immunotoxins (34%), followed by immunocytokines (32.5%). Majority of these therapies are under clinical trials for the treatment of lymphoma (22) followed by solid tumors (19) and leukemia (18). Around 60 industry and non-industry players are engaged in the development of novel antibody therapies, globally North America has emerged as the hub, featuring the presence of approximately 60% developers. The market is currently dominated by the presence of small players (27%). Interestingly, 16% of the players are big pharma companies engaged in the development of such therapeutics for multiple target indications. More than 550 clinical trials have been registered for the evaluation of novel antibody therapies, worldwide The clinical research activity, in terms of number of trials registered, is reported to have increased at a steady CAGR of 8%, during the period 2016-2021. Of the total number of trials registered, close to 60% have already been completed, while 25% of the studies are actively recruiting participants. Close to 600 articles related to novel antibody therapies, have been published in reputed scientific journals, since 2017 More than 95% of the articles focused on novel antibody therapies were published post-2019. Popular journals that have published multiple articles include Cancer, Frontiers in Immunology, International Journal of Molecular Sciences and Scientific Reports. Over 4,600 patents have been filed / granted related to novel antibody therapies, since 2017 More than 1,150 patents were filed / granted in 2021. Further, around 56% of the patents were filed in North America. It is worth highlighting that majority of the patents were granted / filed by prominent industry / non-Industry players, such as Novartis, Hoffmann la Roche, Immatics Biotechnologies and Pfizer. For additional details, please visit https://www.rootsanalysis.com/reports/novel-antibody-therapies-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Novel Antibody Therapies Market | Market Size | 2035
    Novel Antibody Therapies Market, is projected to be worth more than USD 2 Billion by 2035 Growing at an Annualized Rate of Over 20%, driven by popular classes of antibodies
    0 Comments 0 Shares
  • The ADC contract manufacturing market is projected to grow at a CAGR of more than 13% till 2035, claims Roots Analysis

    Owing to the fact that a number of ADC developers are outsourcing various aspects of their business processes, CMOs engaged in this domain have undertaken several expansion initiatives to become one-stop-shops to cater to the diverse needs of ADC developers.

    London

    Roots Analysis has announced the addition of “ADC Contract Manufacturing Market (5th Edition), 2022-2035” report to its list of offerings.

    In order to mitigate the challenges associated with Antibody Drug Conjugate manufacturing, around 70-80% of the therapeutics developers prefer to outsource their operations to contract manufacturing organizations (CMOs), which claim to have the required expertise and experience to leverage their capabilities and yield cost savings opportunities.

    To request a sample copy / brochure of this report, please visit
    https://www.rootsanalysis.com/reports/218/request-sample.html

    Key Market Insights
    Presently, more than 30 players claim to offer ADC contract manufacturing services
    This segment of the industry is dominated by the presence of large (more than 501 employees) and mid-sized (51-500 employees) players, which collectively represent more than 80% of the total contract manufacturers in this domain. In addition, around15% firms were established post 2010.

    More than 84 expansions were reported in this industry, during 2012-2021
    Of the total, 57% instances were focused on enhancing dedicated capabilities and capacities, followed by those carried out for the expansion / establishment of manufacturing facilities (42%).

    Partnership activity in this domain has increased at a CAGR of over 16%, during 2016- 2021
    Manufacturing agreements emerged as the most popular type of partnership model adopted by industry stakeholders (18%), followed by product development agreements (16%) and research agreements (15%). Further, most of the deals were inked by players based in Europe (46%).

    Global, installed ADC contract manufacturing capacity is currently estimated to be close to 33 Kilograms
    The maximum share of the current installed capacity is expected to be captured by large players. Moreover, close to 37% of the installed manufacturing capacity is available in the Asia-Pacific region.

    140,200+ patients have been enrolled in over 714 clinical trials, worldwide
    Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 21%, in the past three years. Of the total number of trials, close to 47% of the studies are recruiting patients, while 30% have been completed.

    Global demand for ADC contract manufacturing is anticipated to grow at a CAGR of 13%, during 2022-2035
    The commercial demand for ADC therapeutics is projected to increase at a CAGR of 22%. Further, the clinical demand for ADC therapeutics in phase III trials is projected to increase at a CAGR of 10%.

    For additional details please visit https://www.rootsanalysis.com/reports/view_document/adc-contract-manufacturing-market/218.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Targeted protein degradation market, 2022-2035
    2. Cell Therapy Manufacturing Market, 2021-2030
    3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/


    The ADC contract manufacturing market is projected to grow at a CAGR of more than 13% till 2035, claims Roots Analysis Owing to the fact that a number of ADC developers are outsourcing various aspects of their business processes, CMOs engaged in this domain have undertaken several expansion initiatives to become one-stop-shops to cater to the diverse needs of ADC developers. London Roots Analysis has announced the addition of “ADC Contract Manufacturing Market (5th Edition), 2022-2035” report to its list of offerings. In order to mitigate the challenges associated with Antibody Drug Conjugate manufacturing, around 70-80% of the therapeutics developers prefer to outsource their operations to contract manufacturing organizations (CMOs), which claim to have the required expertise and experience to leverage their capabilities and yield cost savings opportunities. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/218/request-sample.html Key Market Insights Presently, more than 30 players claim to offer ADC contract manufacturing services This segment of the industry is dominated by the presence of large (more than 501 employees) and mid-sized (51-500 employees) players, which collectively represent more than 80% of the total contract manufacturers in this domain. In addition, around15% firms were established post 2010. More than 84 expansions were reported in this industry, during 2012-2021 Of the total, 57% instances were focused on enhancing dedicated capabilities and capacities, followed by those carried out for the expansion / establishment of manufacturing facilities (42%). Partnership activity in this domain has increased at a CAGR of over 16%, during 2016- 2021 Manufacturing agreements emerged as the most popular type of partnership model adopted by industry stakeholders (18%), followed by product development agreements (16%) and research agreements (15%). Further, most of the deals were inked by players based in Europe (46%). Global, installed ADC contract manufacturing capacity is currently estimated to be close to 33 Kilograms The maximum share of the current installed capacity is expected to be captured by large players. Moreover, close to 37% of the installed manufacturing capacity is available in the Asia-Pacific region. 140,200+ patients have been enrolled in over 714 clinical trials, worldwide Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 21%, in the past three years. Of the total number of trials, close to 47% of the studies are recruiting patients, while 30% have been completed. Global demand for ADC contract manufacturing is anticipated to grow at a CAGR of 13%, during 2022-2035 The commercial demand for ADC therapeutics is projected to increase at a CAGR of 22%. Further, the clinical demand for ADC therapeutics in phase III trials is projected to increase at a CAGR of 10%. For additional details please visit https://www.rootsanalysis.com/reports/view_document/adc-contract-manufacturing-market/218.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - ADC Contract Manufacturing Market | Industry Analysis | Market Size | 2035
    Overall, we expect the ADC contract manufacturing market to grow at an annualized rate of over 12%, during the period 2022-2035
    0 Comments 0 Shares
  • PRESENTLY, MORE THAN 100 PLAYERS ACROSS THE GLOBE CLAIM TO OFFER NUTRIGENOMICS TESTS / SERVICES BASED ON GENETIC ASSESSMENT


    Given the recent shift from the one-size-fits-all model to a more personalized mode of treatment, there has been a growing interest in identification and adoption of novel techniques.

    It is estimated that there are around 20,000 genes present in the human body, all of which interact with the nutrients in the food, either directly or indirectly. Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advances in DNA sequencing technologies have enabled significant developments in a variety of healthcare-focused research fields, such as precision medicine and diagnostics. Further, the success of the Human Genome Project, which mapped the whole human DNA, has paved a path for the novel concept of nutrigenomics, the science studying the relationship between human genome, nutrition and health. One of the key objectives of the report was to evaluate the current opportunity and future potential associated with the nutrigenomics market, over the coming 13 years. We have provided informed estimates of the likely evolution of the nutrigenomics market in the short to mid-term and long term, for the period 2022-2035.

    To request a sample copy / brochure of this report, please visit link
    https://www.rootsanalysis.com/reports/nutrigenomics-market/request-sample.html

    Presently, extensive studies are being conducted to understand the interaction between nutrients and gene expression at the molecular level to determine effect of a specific nutrient and dietary regime on the human health. Although the field of nutritional genomics is still in a nascent stage, it is a moving at a very fast-pace and is believed to have the potential to lay the foundation for personalized nutrition offerings. Further, the growing interest in nutrigenomics is supported by the rising awareness about the influence of diet on human health and its potential with respect to minimizing the risk of various diet-related diseases, including diabetes, cardiovascular disorders, chronic respiratory diseases and oncological disorders. It is worth mentioning that there are several companies that provide nutrigenomic test offerings directly to consumer, through availability of online genetic test kits and at-home sample collection facilities. Moreover, this field is evolving continuously, as researchers and industry players alike aim to enhance the existing offerings.

    This field is evolving continuously, as researchers and industry players alike aim to enhance the existing offerings. In this context, in the past 3 years, over 135 nutrigenomics focused research articles have been published, highlighting the active initiatives of researchers to illustrate the effect of nutrition on regulation of gene expression. At present, there are some ethical and regulatory challenges associated with nutrigenomics, including the potential misuse of personal data, as well as uncertainty related to genetic phenotypic predispositions, for conditions where no proven treatment exists. However, the benefits offered by nutrigenomics outweigh the uncertainty associated with its adoption. Considering the growing focus on personalized diets and active initiatives being undertaken by players in this domain, we are led to believe that the opportunity for stakeholders in this niche, but upcoming, industry is likely to grow at a commendable pace in the foreseen future.

    For additional details, please visit link https://www.rootsanalysis.com/reports/nutrigenomics-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Targeted protein degradation market, 2022-2035
    2. Cell Therapy Manufacturing Market, 2021-2030
    3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    PRESENTLY, MORE THAN 100 PLAYERS ACROSS THE GLOBE CLAIM TO OFFER NUTRIGENOMICS TESTS / SERVICES BASED ON GENETIC ASSESSMENT Given the recent shift from the one-size-fits-all model to a more personalized mode of treatment, there has been a growing interest in identification and adoption of novel techniques. It is estimated that there are around 20,000 genes present in the human body, all of which interact with the nutrients in the food, either directly or indirectly. Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advances in DNA sequencing technologies have enabled significant developments in a variety of healthcare-focused research fields, such as precision medicine and diagnostics. Further, the success of the Human Genome Project, which mapped the whole human DNA, has paved a path for the novel concept of nutrigenomics, the science studying the relationship between human genome, nutrition and health. One of the key objectives of the report was to evaluate the current opportunity and future potential associated with the nutrigenomics market, over the coming 13 years. We have provided informed estimates of the likely evolution of the nutrigenomics market in the short to mid-term and long term, for the period 2022-2035. To request a sample copy / brochure of this report, please visit link https://www.rootsanalysis.com/reports/nutrigenomics-market/request-sample.html Presently, extensive studies are being conducted to understand the interaction between nutrients and gene expression at the molecular level to determine effect of a specific nutrient and dietary regime on the human health. Although the field of nutritional genomics is still in a nascent stage, it is a moving at a very fast-pace and is believed to have the potential to lay the foundation for personalized nutrition offerings. Further, the growing interest in nutrigenomics is supported by the rising awareness about the influence of diet on human health and its potential with respect to minimizing the risk of various diet-related diseases, including diabetes, cardiovascular disorders, chronic respiratory diseases and oncological disorders. It is worth mentioning that there are several companies that provide nutrigenomic test offerings directly to consumer, through availability of online genetic test kits and at-home sample collection facilities. Moreover, this field is evolving continuously, as researchers and industry players alike aim to enhance the existing offerings. This field is evolving continuously, as researchers and industry players alike aim to enhance the existing offerings. In this context, in the past 3 years, over 135 nutrigenomics focused research articles have been published, highlighting the active initiatives of researchers to illustrate the effect of nutrition on regulation of gene expression. At present, there are some ethical and regulatory challenges associated with nutrigenomics, including the potential misuse of personal data, as well as uncertainty related to genetic phenotypic predispositions, for conditions where no proven treatment exists. However, the benefits offered by nutrigenomics outweigh the uncertainty associated with its adoption. Considering the growing focus on personalized diets and active initiatives being undertaken by players in this domain, we are led to believe that the opportunity for stakeholders in this niche, but upcoming, industry is likely to grow at a commendable pace in the foreseen future. For additional details, please visit link https://www.rootsanalysis.com/reports/nutrigenomics-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Nutrigenomics Market | Size | Trends Industry Analysis | 2035
    Driven by 100+ companies offering nutrigenomics test and affiliated services and ongoing innovation, we anticipate the nutrigenomics market to grow at around 13% CAGR
    0 Comments 0 Shares
  • The viral vector, non-viral vector and gene therapy manufacturing market is projected to grow at a CAGR of ~15% till 2035, claims Roots Analysis

    Rise in clinical research activity for genetically modified therapies has resulted in the increase in demand for vectors, offering lucrative opportunities to players having capabilities for in-house and contract manufacturing of various types of vectors.

    Roots Analysis has announced the addition of “Viral Vector, Non-Viral Vector and Gene Therapy Manufacturing Market (5th Edition), 2022-2035” report to its list of offerings.

    The viral vector manufacturing and non-viral vector manufacturing landscape features a mix of industry players (well-established companies, mid-sized firms and start-ups / small companies), as well as several academic institutes. Over the past few years, cell and gene therapies have gained significant popularity owing to their therapeutic potential. In fact, more than 20 genetically modified therapies have already been approved, which has resulted in the increase in demand for vectors, which have proven to be highly efficient for the delivery of genetic material to the targeted area. In order to cater to the growing demand, several companies are offering diverse range of services for vector and gene therapy manufacturing.

    To request a sample copy / brochure of this report, please visit link
    https://www.rootsanalysis.com/reports/274/request-sample.html

    Key Market Insights

    More than 140 stakeholders claim to manufacture viral and non-viral vectors
    The market is currently dominated by the presence of various mid-sized industry players (50%); of these 57% of players are contract manufacturers, whereas 22% of players are in-house manufacturers.

    Over the time, several advancements have been made for the development of vector based technological platforms
    Majority (37%) of the available technologies are currently used in vector manufacturing followed by those available for manufacturing of cell and gene therapies (16%). Further, 53% of the vector-based technologies are dedicated for the development and manufacturing of adenoviral vectors.

    More than 295 partnerships were established between different stakeholders during the last decade
    Close to 55% partnerships have been reported post 2018, wherein, maximum partnerships were recorded in year 2022 (till May). Further, maximum partnerships were related to manufacturing (23%) followed by licensing agreement (20%) and product development agreement (15%).

    Close to 120 expansion activities have been recorded till 2022, growing at a CAGR of 10%
    Majority of the expansions in this domain were related to the establishment of new facility (39%) followed by facility expansion (12%).

    The installed vector manufacturing capacity is estimated to be ~186,150 L
    Majority (70%) of total installed capacity is currently available for clinical / commercial stage manufacturing of viral vectors. Further, players headquartered in North America (56%) have the highest installed capacity, across the globe.

    For additional details, please visit link https://www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/274.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Targeted protein degradation market, 2022-2035
    2. Cell Therapy Manufacturing Market, 2021-2030
    3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/

    The viral vector, non-viral vector and gene therapy manufacturing market is projected to grow at a CAGR of ~15% till 2035, claims Roots Analysis Rise in clinical research activity for genetically modified therapies has resulted in the increase in demand for vectors, offering lucrative opportunities to players having capabilities for in-house and contract manufacturing of various types of vectors. Roots Analysis has announced the addition of “Viral Vector, Non-Viral Vector and Gene Therapy Manufacturing Market (5th Edition), 2022-2035” report to its list of offerings. The viral vector manufacturing and non-viral vector manufacturing landscape features a mix of industry players (well-established companies, mid-sized firms and start-ups / small companies), as well as several academic institutes. Over the past few years, cell and gene therapies have gained significant popularity owing to their therapeutic potential. In fact, more than 20 genetically modified therapies have already been approved, which has resulted in the increase in demand for vectors, which have proven to be highly efficient for the delivery of genetic material to the targeted area. In order to cater to the growing demand, several companies are offering diverse range of services for vector and gene therapy manufacturing. To request a sample copy / brochure of this report, please visit link https://www.rootsanalysis.com/reports/274/request-sample.html Key Market Insights More than 140 stakeholders claim to manufacture viral and non-viral vectors The market is currently dominated by the presence of various mid-sized industry players (50%); of these 57% of players are contract manufacturers, whereas 22% of players are in-house manufacturers. Over the time, several advancements have been made for the development of vector based technological platforms Majority (37%) of the available technologies are currently used in vector manufacturing followed by those available for manufacturing of cell and gene therapies (16%). Further, 53% of the vector-based technologies are dedicated for the development and manufacturing of adenoviral vectors. More than 295 partnerships were established between different stakeholders during the last decade Close to 55% partnerships have been reported post 2018, wherein, maximum partnerships were recorded in year 2022 (till May). Further, maximum partnerships were related to manufacturing (23%) followed by licensing agreement (20%) and product development agreement (15%). Close to 120 expansion activities have been recorded till 2022, growing at a CAGR of 10% Majority of the expansions in this domain were related to the establishment of new facility (39%) followed by facility expansion (12%). The installed vector manufacturing capacity is estimated to be ~186,150 L Majority (70%) of total installed capacity is currently available for clinical / commercial stage manufacturing of viral vectors. Further, players headquartered in North America (56%) have the highest installed capacity, across the globe. For additional details, please visit link https://www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/274.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing | Market Size | 2035
    The viral vector and gene therapy market, is projected to be worth more than USD 2 Billion by 2035 Growing at an Annualized Rate of Over 20%
    0 Comments 0 Shares
  • RNAI THERAPY OFFERS THE POTENTIAL TO REVOLUTIONIZE THE BIOPHARMACEUTICAL INDUSTRY

    Owing to their vast potential in controlling disease-associated gene expression, RNAi therapeutics have emerged as a key segment of the market; several big pharma players have undertaken RNAi focused initiatives.

    In addition to effective gene silencing, these candidates can be deployed for applications related to precision medicine. Studies have also demonstrated the safety of RNAi therapeutics for in systemic delivery, paving the way for systemic applications of the therapy. A number of novel and sophisticated technologies / platforms have been / are being developed to overcome the challenges associated with RNAi therapeutics, as well as further enhance their specificity and stability. Further, considering their high knockdown efficiency, high target specificity and extended silencing ability, RNAi has now been established as a powerful tool for gene silencing. It is worth highlighting, RNAi has potential applications in treating several viral infections and tumors in addition to its ability in gene function determination. However, despite the numerous benefits offered by RNAi therapies, developers often face concerns related to the stability and targeted delivery of their candidates. In order to mitigate the aforementioned challenges, several players have developed novel technologies and delivery systems to ensure target specific delivery of these molecules.

    To request a sample copy / brochure of this report, please visit
    https://www.rootsanalysis.com/reports/278/request-sample.html

    With four approved drugs and several therapy candidates being evaluated in late stages of clinical development, the RNAi therapeutics domain presents a significant opportunity for biopharmaceutical developers. In addition, a number of RNAi therapeutics are being developed to target rare and genetic clinical conditions, such as Alpha 1-Antitrypsin Disease, Alport Syndrome, Amyloidosis and Muscular Dystrophy (Facioscapulohumeral Muscular Dystrophy and Oculopharyngeal Muscular Dystrophy). It is also worth highlighting that over 2,100 patents have been filed / granted, highlighting the continuous pace of ongoing innovation in this field. Given the high research activity and ongoing technology advancements, the RNAi therapeutics market is poised to grow at a steady pace in the foreseen future. An insightful technology competitiveness analysis, benchmarking RNAi technologies, based on supplier power (in terms of company size and years of experience) and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.



    For additional details please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market/278.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Targeted protein degradation market, 2022-2035
    2. Cell Therapy Manufacturing Market, 2021-2030
    3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    RNAI THERAPY OFFERS THE POTENTIAL TO REVOLUTIONIZE THE BIOPHARMACEUTICAL INDUSTRY Owing to their vast potential in controlling disease-associated gene expression, RNAi therapeutics have emerged as a key segment of the market; several big pharma players have undertaken RNAi focused initiatives. In addition to effective gene silencing, these candidates can be deployed for applications related to precision medicine. Studies have also demonstrated the safety of RNAi therapeutics for in systemic delivery, paving the way for systemic applications of the therapy. A number of novel and sophisticated technologies / platforms have been / are being developed to overcome the challenges associated with RNAi therapeutics, as well as further enhance their specificity and stability. Further, considering their high knockdown efficiency, high target specificity and extended silencing ability, RNAi has now been established as a powerful tool for gene silencing. It is worth highlighting, RNAi has potential applications in treating several viral infections and tumors in addition to its ability in gene function determination. However, despite the numerous benefits offered by RNAi therapies, developers often face concerns related to the stability and targeted delivery of their candidates. In order to mitigate the aforementioned challenges, several players have developed novel technologies and delivery systems to ensure target specific delivery of these molecules. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/278/request-sample.html With four approved drugs and several therapy candidates being evaluated in late stages of clinical development, the RNAi therapeutics domain presents a significant opportunity for biopharmaceutical developers. In addition, a number of RNAi therapeutics are being developed to target rare and genetic clinical conditions, such as Alpha 1-Antitrypsin Disease, Alport Syndrome, Amyloidosis and Muscular Dystrophy (Facioscapulohumeral Muscular Dystrophy and Oculopharyngeal Muscular Dystrophy). It is also worth highlighting that over 2,100 patents have been filed / granted, highlighting the continuous pace of ongoing innovation in this field. Given the high research activity and ongoing technology advancements, the RNAi therapeutics market is poised to grow at a steady pace in the foreseen future. An insightful technology competitiveness analysis, benchmarking RNAi technologies, based on supplier power (in terms of company size and years of experience) and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry. For additional details please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market/278.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - RNAi Therapeutics and Technologies Market | Industry Analysis | Market Size | 2035
    The RNAi market: Therapeutics and Technologies features an extensive study of the current market landscape and the likely future potential; associated with the RNAi therapeutics market....
    0 Comments 0 Shares
  • The taste masking market is anticipated to grow at a steady pace till 2035, claims Roots Analysis

    Driven by the growing need to enhance palatability of oral drugs and drug adherence among pediatric and geriatric population, the demand for novel and advanced taste masking and taste assessment technologies is expected to rise in the coming years.

    London

    Roots Analysis has announced the addition of “Taste masking and Taste Assessment Services and Technologies Market, 2022-2035” report to its list of offerings.

    The inherent expertise of CMOs and CDMOs in taste masking and taste assessment of bitter drug formulations, along with capabilities to identify globally accepted tastes, develop flavor matching placebo formulations (for testing) having compliance with stringent regulatory guidelines and good clinical practices (GCPs) and proprietary technologies offering significant cost-benefits, have rendered outsourcing as a crucial aspect of taste masked formulation development and production.

    Key Market Insights

    Presently, 50 companies claim to offer taste masking and taste assessment services for oral drug formulations
    Majority (40%, each) of the service providers are based in North America and Europe, followed by companies headquartered in Asia-Pacific (18%). A large proportion (34%) of these companies are large players, followed by small (31%) and mid-sized firms (27%).

    Close to 30 technology platforms have been developed for taste masking and taste assessment of oral drug formulations
    Majority (68%) of the technology platforms are used for taste masking and taste assessment of solid oral formulations (tablets, capsules, granules and powder), followed by liquid (10%) oral formulations (suspensions, syrups and solutions).

    Partnership activity in this field has grown significantly between 2018 and 2021
    The maximum number of partnerships were established in 2021 indicating a recent rise in the interest of players engaged in the field of taste masking and taste assessment. It is worth highlighting that majority of the agreements were related to acquisition, representing 46% of the total number of partnerships signed. This is followed by agreements signed for manufacturing of oral drug formulation (13%).

    More than 460 patents have been filed / granted for taste masking and taste assessment techniques and technologies, since 2017
    Close to 60% of the patent applications have been filed by various industry and non-industry players in this domain post 2018. It is worth noting that, around 75% of the patents were filed / granted in the US, followed by European Patent Office (25%).

    North America is anticipated to capture larger share of the market by 2035
    The taste masking market is likely to be driven by technology platforms that employ coating techniques. Further, solid formulations are likely to hold greater market share.


    To request a sample copy / brochure of this report, please visit
    https://www.rootsanalysis.com/reports/taste-masking-services-market/request-sample.html


    The report features inputs from eminent industry stakeholders, who were very optimistic concerning the need of outsourcing of taste masking and taste assessment services in the coming decade. The report includes detailed transcripts of the discussions held with the following industry experts:

     Phillipe Tschopp (Head of Business Development, Glatt Pharmaceutical Services)
     David Tisi (Director of Technical Operations, Senopsys)
     Brandon Keener (Business Development Associate, Adare Pharma Solutions)

    For additional details, please visit https://www.rootsanalysis.com/reports/taste-masking-services-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Targeted protein degradation market, 2022-2035
    2. Cell Therapy Manufacturing Market, 2021-2030
    3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The taste masking market is anticipated to grow at a steady pace till 2035, claims Roots Analysis Driven by the growing need to enhance palatability of oral drugs and drug adherence among pediatric and geriatric population, the demand for novel and advanced taste masking and taste assessment technologies is expected to rise in the coming years. London Roots Analysis has announced the addition of “Taste masking and Taste Assessment Services and Technologies Market, 2022-2035” report to its list of offerings. The inherent expertise of CMOs and CDMOs in taste masking and taste assessment of bitter drug formulations, along with capabilities to identify globally accepted tastes, develop flavor matching placebo formulations (for testing) having compliance with stringent regulatory guidelines and good clinical practices (GCPs) and proprietary technologies offering significant cost-benefits, have rendered outsourcing as a crucial aspect of taste masked formulation development and production. Key Market Insights Presently, 50 companies claim to offer taste masking and taste assessment services for oral drug formulations Majority (40%, each) of the service providers are based in North America and Europe, followed by companies headquartered in Asia-Pacific (18%). A large proportion (34%) of these companies are large players, followed by small (31%) and mid-sized firms (27%). Close to 30 technology platforms have been developed for taste masking and taste assessment of oral drug formulations Majority (68%) of the technology platforms are used for taste masking and taste assessment of solid oral formulations (tablets, capsules, granules and powder), followed by liquid (10%) oral formulations (suspensions, syrups and solutions). Partnership activity in this field has grown significantly between 2018 and 2021 The maximum number of partnerships were established in 2021 indicating a recent rise in the interest of players engaged in the field of taste masking and taste assessment. It is worth highlighting that majority of the agreements were related to acquisition, representing 46% of the total number of partnerships signed. This is followed by agreements signed for manufacturing of oral drug formulation (13%). More than 460 patents have been filed / granted for taste masking and taste assessment techniques and technologies, since 2017 Close to 60% of the patent applications have been filed by various industry and non-industry players in this domain post 2018. It is worth noting that, around 75% of the patents were filed / granted in the US, followed by European Patent Office (25%). North America is anticipated to capture larger share of the market by 2035 The taste masking market is likely to be driven by technology platforms that employ coating techniques. Further, solid formulations are likely to hold greater market share. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/taste-masking-services-market/request-sample.html The report features inputs from eminent industry stakeholders, who were very optimistic concerning the need of outsourcing of taste masking and taste assessment services in the coming decade. The report includes detailed transcripts of the discussions held with the following industry experts:  Phillipe Tschopp (Head of Business Development, Glatt Pharmaceutical Services)  David Tisi (Director of Technical Operations, Senopsys)  Brandon Keener (Business Development Associate, Adare Pharma Solutions) For additional details, please visit https://www.rootsanalysis.com/reports/taste-masking-services-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Taste Masking and Taste Assessment | Industry Analysis | Market Size | 2035
    Taste Masking and Taste Assessment Service and Technology Market report features a detailed study of the current scenario and future potential of the DNA synthesis...
    0 Comments 0 Shares
  • The DNA and gene cloning services market is anticipated to grow at a CAGR of over 15% by 2035, claims Roots Analysis

    In order to avail benefits, such as technical competence, reduced cost, and fast delivery of high-quality DNA and gene customized clones, several players have demonstrated a preference to leverage expertise of DNA and gene cloning service providers.

    London

    Roots Analysis has announced the addition of “DNA and Gene Cloning Market , 2022-2035” report to its list of offerings.

    DNA and gene cloning have diverse applications, including modern biotechnological, medicinal, and several diagnostic ones as DNA and gene cloning has proven to be beneficial for research and development in the biopharmaceutical and healthcare industries. Presently, a number of players having dedicated facilities, cutting-edge machinery, and production lines, are offering DNA and gene cloning services to the various stakeholders in this domain. In 1973, a group of scientists reported that individual genes can be cloned and isolated by cleaving DNA enzymatically into DNA fragments. Over time, gene and DNA cloning has proved to be an important tool for researchers in their studies focused on genetics

    Key Market Insights

    Around 80 companies claim to offer DNA and gene cloning services, globally
    Majority (59%) of the stakeholders are headquartered in North America, followed by those based in Europe (22%), and Asia-Pacific (19%). Further, this segment of the industry is dominated by the presence of small players (11-50 employees), representing 35% of the total service providers.

    Close to 32% players claim to act as one-stop-shops, offering services for gene synthesis, custom cloning, and sub-cloning
    Close to 80% of the DNA and gene cloning service providers offer custom cloning, followed by companies offering gene synthesis (68%), sub-cloning (50%), and other services, such as RNA cloning and vector cloning (31%). It is worth mentioning that most of the service providers (61%) offer restriction enzyme-based cloning.

    Close to 6,900 articles related to DNA and gene cloning, have been published in reputed scientific journals since 2018
    More than 45% of the articles focused on DNA and gene cloning were published post-2019. Popular journals that have published multiple articles include Methods in Molecular Biology, International Journal of Biological Macromolecules, Developmental and Comparative Immunology, Protein Expression and Purification, and International Journal of Molecular Sciences.

    To request a sample copy / brochure of this report, please visit link
    https://www.rootsanalysis.com/reports/dna-and-gene-cloning-market/request-sample.html

    For additional details, please visit
    https://www.rootsanalysis.com/reports/dna-and-gene-cloning-market.html
    or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Targeted protein degradation market, 2022-2035
    2. Cell Therapy Manufacturing Market, 2021-2030
    3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/

    The DNA and gene cloning services market is anticipated to grow at a CAGR of over 15% by 2035, claims Roots Analysis In order to avail benefits, such as technical competence, reduced cost, and fast delivery of high-quality DNA and gene customized clones, several players have demonstrated a preference to leverage expertise of DNA and gene cloning service providers. London Roots Analysis has announced the addition of “DNA and Gene Cloning Market , 2022-2035” report to its list of offerings. DNA and gene cloning have diverse applications, including modern biotechnological, medicinal, and several diagnostic ones as DNA and gene cloning has proven to be beneficial for research and development in the biopharmaceutical and healthcare industries. Presently, a number of players having dedicated facilities, cutting-edge machinery, and production lines, are offering DNA and gene cloning services to the various stakeholders in this domain. In 1973, a group of scientists reported that individual genes can be cloned and isolated by cleaving DNA enzymatically into DNA fragments. Over time, gene and DNA cloning has proved to be an important tool for researchers in their studies focused on genetics Key Market Insights Around 80 companies claim to offer DNA and gene cloning services, globally Majority (59%) of the stakeholders are headquartered in North America, followed by those based in Europe (22%), and Asia-Pacific (19%). Further, this segment of the industry is dominated by the presence of small players (11-50 employees), representing 35% of the total service providers. Close to 32% players claim to act as one-stop-shops, offering services for gene synthesis, custom cloning, and sub-cloning Close to 80% of the DNA and gene cloning service providers offer custom cloning, followed by companies offering gene synthesis (68%), sub-cloning (50%), and other services, such as RNA cloning and vector cloning (31%). It is worth mentioning that most of the service providers (61%) offer restriction enzyme-based cloning. Close to 6,900 articles related to DNA and gene cloning, have been published in reputed scientific journals since 2018 More than 45% of the articles focused on DNA and gene cloning were published post-2019. Popular journals that have published multiple articles include Methods in Molecular Biology, International Journal of Biological Macromolecules, Developmental and Comparative Immunology, Protein Expression and Purification, and International Journal of Molecular Sciences. To request a sample copy / brochure of this report, please visit link https://www.rootsanalysis.com/reports/dna-and-gene-cloning-market/request-sample.html For additional details, please visit https://www.rootsanalysis.com/reports/dna-and-gene-cloning-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - DNA Cloning and Gene Cloning Services | Industry Analysis | Market Size | 2035
    DNA Cloning and Gene Cloning Services Market expected to grow rapidly at a CGAR of more than 15%, representative of rapid future market opportunity till 2035
    0 Comments 0 Shares
  • The mini bioreactors and microbioreactors market is anticipated to grow at an annualized rate of 8% till 2035, claims Roots Analysis

    Given the need for accelerated bioprocessing operations, low-volume bioreactors have emerged as a relatively economic solution for parallelized cell cultivations and applications ranging from media development to process optimization

    Roots Analysis has announced the addition of “Mini Bioreactors and Micro Bioreactors Market, 2022-2035” report to its list of offerings.

    Mini bioreactors and microbioreactors enable faster experimental throughput at relatively lower costs and allow bioprocessing of samples, thereby reducing the downtime and increasing the number of batches produced in a given period of time. Moreover, stakeholders in this domain are also focused on incorporating a variety of features for monitoring of different control parameters, such as CO2 levels, dissolved oxygen, pH and temperature ranges, in order to analyze and determine essential conditions of the culture environment and optimize the overall performance.

    Key Market Insights

    Currently, over 60 mini bioreactors and micro bioreactors are available in the market
    Majority (55%) of these equipment are single-use bioreactors, followed by reusable bioreactors, which constitute around 24% of the total number of mini bioreactors and micro bioreactors available in the market.

    More than 25 companies are engaged in the development of mini bioreactors and micro bioreactors
    The current market landscape features the presence of both well-established players and new entrants; however, more than 70% of the players are small and mid-sized companies. Further, majority (more than 57%) of the developers are headquartered in Europe, followed by North America (25%) and Asia-Pacific (18%).

    More than 250 patents related to mini bioreactors and micro bioreactors, were filed since 2016
    Of these, over 70% were patent applications, while around 28% were granted patents. Of the total granted patents, close to 42% were filed in North America, followed by WIPO (36%), Europe (14%) and Asia-Pacific (8%).

    North America is anticipated to capture over 35% of the global market share in 2035
    Mini bioreactors and micro bioreactors developed for batch / fed-batch operations are likely to capture the highest market share (90%). Further, in terms of revenues generated from the product sales, North America is likely to capture the maximum share in the global market, followed by Europe (31%) and Asia Pacific (22%).

    To request a sample copy / brochure of this report, please visit link https://www.rootsanalysis.com/reports/mini-bioreactors-market/request-sample.html

    For additional details, please visit link https://www.rootsanalysis.com/reports/mini-bioreactors-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Targeted protein degradation market, 2022-2035
    2. Cell Therapy Manufacturing Market, 2021-2030
    3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/

    The mini bioreactors and microbioreactors market is anticipated to grow at an annualized rate of 8% till 2035, claims Roots Analysis Given the need for accelerated bioprocessing operations, low-volume bioreactors have emerged as a relatively economic solution for parallelized cell cultivations and applications ranging from media development to process optimization Roots Analysis has announced the addition of “Mini Bioreactors and Micro Bioreactors Market, 2022-2035” report to its list of offerings. Mini bioreactors and microbioreactors enable faster experimental throughput at relatively lower costs and allow bioprocessing of samples, thereby reducing the downtime and increasing the number of batches produced in a given period of time. Moreover, stakeholders in this domain are also focused on incorporating a variety of features for monitoring of different control parameters, such as CO2 levels, dissolved oxygen, pH and temperature ranges, in order to analyze and determine essential conditions of the culture environment and optimize the overall performance. Key Market Insights Currently, over 60 mini bioreactors and micro bioreactors are available in the market Majority (55%) of these equipment are single-use bioreactors, followed by reusable bioreactors, which constitute around 24% of the total number of mini bioreactors and micro bioreactors available in the market. More than 25 companies are engaged in the development of mini bioreactors and micro bioreactors The current market landscape features the presence of both well-established players and new entrants; however, more than 70% of the players are small and mid-sized companies. Further, majority (more than 57%) of the developers are headquartered in Europe, followed by North America (25%) and Asia-Pacific (18%). More than 250 patents related to mini bioreactors and micro bioreactors, were filed since 2016 Of these, over 70% were patent applications, while around 28% were granted patents. Of the total granted patents, close to 42% were filed in North America, followed by WIPO (36%), Europe (14%) and Asia-Pacific (8%). North America is anticipated to capture over 35% of the global market share in 2035 Mini bioreactors and micro bioreactors developed for batch / fed-batch operations are likely to capture the highest market share (90%). Further, in terms of revenues generated from the product sales, North America is likely to capture the maximum share in the global market, followed by Europe (31%) and Asia Pacific (22%). To request a sample copy / brochure of this report, please visit link https://www.rootsanalysis.com/reports/mini-bioreactors-market/request-sample.html For additional details, please visit link https://www.rootsanalysis.com/reports/mini-bioreactors-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Mini Bioreactors and Micro Bioreactors Market | Market Size | 2035
    Mini Bioreactor and Micro Bioreactor Market, is Projected to be Worth USD 10 Billion by 2035 Growing at an Annualized Rate of Over 40%
    0 Comments 0 Shares
More Stories